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Epidemiological evidence shows that consumption of dairy products is associated with decreased prevalence of
metabolic related disorders, whilst evidence from experimental studies points towards dairy protein as a dietary
component which may aid prevention of type 2 diabetes (T2DM). Poor metabolic health is a common characteristic
of overweight, obesity and aging, and is the forerunner of T2DM and cardiovascular disease (CVD), and an ever
increasing global health issue. Progressive loss of metabolic control is evident from a blunting of carbohydrate, fat
and protein metabolism, which is commonly manifested through decreased insulin sensitivity, inadequate glucose
and lipid control, accompanied by a pro-inflammatory environment and hypertension. Adverse physiological
changes such as excess visceral adipose tissue deposition and expansion, lipid overspill and infiltration into liver,
muscle and other organs, and sarcopaenia or degenerative loss of skeletal muscle mass and function all underpin
this adverse profile. ‘Sarcobesity’ and sarcopaenic diabetes are rapidly growing health issues. As well as through
direct mechanisms, dairy protein may indirectly improve metabolic health by aiding loss of body weight and fat
mass through enhanced satiety, whilst promoting skeletal muscle growth and function through anabolic effects of
dairy protein-derived branch chain amino acids (BCAAs). BCAAs enhance muscle protein synthesis, lean body mass
and skeletal muscle metabolic function. The composition and processing of dairy protein has an impact on
digestion, absorption, BCAA kinetics and function, hence the optimisation of dairy protein composition through
selection and combination of specific protein components in milk may provide a way to maximize benefits for
metabolic health.
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Poor metabolic health represents an ever increasing
global epidemic based on estimates from countries as far
ranging as the US and China [1,2]. Encompassed within
metabolic health are the cluster of interrelated adverse
metabolic markers of hyperglycaemia, dyslipidaemia and
hypertension which alongside central or abdominal
obesity have been termed the metabolic syndrome [3,4].
Individuals with metabolic syndrome are at twice the
risk of developing cardiovascular disease (CVD) within
5-10 years, in addition to a 5-fold increase in risk of* Correspondence: r.mcgregor@auckland.ac.nz
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distribution, and reproduction in any mediumdeveloping T2DM [3], and therefore maintenance of
good metabolic health is critically important.
A continuum of metabolic health exists from young,
lean, healthy individuals with good physiological control
to those with impaired metabolic regulation who are com-
monly overweight or obese, as well as older. Progressive
loss of metabolic control is characterized by a range of
physiological changes which include excess adipose de-
position, lipid overspill, infiltration and accumulation in
key organs such as liver and skeletal muscle, alongside
blunting of carbohydrate (CHO), fat and protein metabol-
ism, decreased insulin sensitivity and hyperglycaemia,
dyslipidaemia, increased inflammation, impaired endothe-
lial function [5], and blunted muscle protein synthesis and
decreased muscle mass, structure and function [6]. Mul-
tiple factors may contribute to the progressive loss of meta-
bolic control, but obesity, ageing and physical inactivity ared Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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health [3,4].
Obesity is of particular importance and a prolonged
positive energy balance with subsequent lipid deposition
and expansion of adipose depots [7], particularly visceral
depots which secrete inflammatory cytokines, play a role
in insulin resistance and decreased insulin-mediated
glucose uptake [8]. Lipid turnover is decreased and
mitochondrial oxidation is suppressed in obese subjects,
promoting intracellular accumulation of lipids and the
buildup of deleterious lipid metabolites in multiple
tissues including skeletal muscle, liver, pancreatic beta
cells, kidney and hypothalamus amongst others [9].
Subsequently, infiltration of inflammatory cells to clear
toxic metabolic byproducts is accompanied by release of
inflammatory cytokines that inhibit metabolic signaling
pathways [10], as well as promote cell death, tissue fibro-
sis and functional impairment. The recommended treat-
ment to improve metabolic health includes changes in
diet and physical activity, which promote adipose tissue
loss, enhance metabolically active skeletal muscle mass
and hence improve metabolic control [5]. Energy re-
stricted diets are widely recommended for weight-loss in
overweight or obese individuals with poor metabolic
health, however ~25% of body weight loss can be attrib-
utable to decreases in skeletal muscle mass [11-13]. Loss
of skeletal muscle is undesirable because it is essential
for mobility and activities of daily living. In addition,
skeletal muscle also plays a major role in glycaemic con-
trol accounting for up to 75% of tissue glucose uptake.
Mitochondrial oxidative capacity is decreased in obese
skeletal muscle, as well as in T2DM, possibly due to
underlying physical inactivity [14].
Advancing age and a sedentary lifestyle are also risk fac-
tors for a gradual loss of skeletal muscle mass, function and
in turn muscle strength. The problem is commonly com-
pounded by increased adipose tissue accumulation and
myocellular lipid infiltration which provides the basis of
sarcopenic (accelerated muscle loss) obesity, and which in
turn may drive insulin resistance and increase metabolic
risk [15]. Intramyocellular lipid accumulation in obese indi-
viduals appears to be difficult to reverse through weight-
loss interventions [16]. Activation of skeletal muscle pro-
tein anabolism appears to be blunted in both the obese [17]
and the elderly, although again this may be attributable to a
common underlying physical inactivity and insulin resist-
ance [6,18]. If metabolic health does not improve with diet
or exercise interventions, pharmacological agents can be
resorted to in order to manage dyslipidaemia, hypertension
and hyperglycemia and loss of metabolic homeostasis.
Currently, there is considerable interest in the use of
dairy proteins as supplements or in conjunction with
lifestyle changes to improve metabolic health [19-23].
Evidence from some epidemiological studies suggest thatgreater consumption of dairy products is associated with
lower risk of metabolic related disorders and CVD
[20,24]. Multiple dairy components in milk such as whey
protein, casein and minerals have been posited as drivers
of these beneficial effects [20], and there is a growing body
of intervention studies assessing the effects of cow’s milk-
derived proteins [23] or peptides on metabolic health [25].
The focus of many of these interventions has been the
whey component of milk, which may act to improve
cardiometabolic risk factors. Whey protein has been
shown to be an insulin secretagogue [26], as well as to im-
prove body weight and adiposity through increased satiety
[19]. In addition to a dietary strategy to promote adipose
loss, dairy proteins have also been shown to increase skel-
etal muscle mass through stimulation of muscle protein
synthesis [27]. Peptides derived from dairy protein have
also been widely investigated as potential inhibitors of
angiotensin-converting enzyme (ACE), thereby regulating
blood pressure [28], and may influence activation of the
innate immune system and inflammation [29].
Milk processing, protein composition and kinetics
Dairy protein consumed by humans is predominantly
from cow’s milk, which consists of around 80% (w/w) ca-
sein, 20% (w/w) whey proteins and is also a rich source of
minerals such as calcium. The casein in cow’s milk com-
prises alpha-s1, alpha-s2, beta and kappa-casein, whilst
whey comprises multiple globular proteins including beta-
lactoglobulin, alpha-lactalbumin, lactoferrin, immunoglo-
bulins, serum albumin, glycomacropeptide, enzymes and
growth factors. All of these components have potential to
contribute to the observed association between increased
consumption of dairy products and decreased risk of
metabolic disease observed in several epidemiological
studies [20,30,31].
Cow’s milk processing
Cow’s milk processing is an important factor determin-
ing the composition, concentration and physiological
effects of whey protein or casein [32,33]. Milk is com-
monly separated into different protein fractions for dif-
ferent food applications [34]. Milk protein concentrate
(MPC), produced by ultrafiltration of skimmed milk,
contains both casein and whey proteins in similar pro-
portions to whole milk, but the total amount of protein,
lactose and mineral content may vary between different
MPC formulations. Micellar casein can be extracted
from milk protein concentrate by further ultrafiltration.
Casein is produced from skim milk by acid precipitation
or enzymatic coagulation, washing and drying. Caseinates
are produced by treatment of acidified or coagulated ca-
sein curd with alkali such as sodium hydroxide or calcium
hydroxide, which forms sodium or calcium caseinates re-
spectively; caseinates contain ~90% protein. Whey protein
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enzyme rennet or acid, resulting in separation of curds
and whey, further ultrafiltration and drying produces whey
protein concentrates containing ~25-80% protein. Add-
itional processing can produce whey protein isolates con-
taining >90% protein with very low amounts of lactose
and lipids. Hydrolysis with enzymes or acids provides a
way to breakdown the structure of whey or casein. In
metabolic-related studies a range of processed milk pro-
teins have been used including milk protein concentrate,
micellar casein, casein, sodium caseinate, calcium casein-
ate, casein hydrolysate, whey protein concentrate, whey
protein isolate and whey protein hydrolysate, as well as a
range of whey and casein peptides.
Amino acid profile of milk proteins
Whey protein and casein are both classified as high
quality proteins based on human amino acid (AA)
requirements, digestibility and their bioavailability. They
contain a relatively high proportion of indispensible
AAs, score higher than most other protein sources
across a wide range of assessment methods including
the protein digestibility corrected AA score (PDCAAS)
[35] and recently developed digestible indispensable
amino acid score (DIAAS) method [36]. Nevertheless,
differences in the physiological effects of whey protein
and casein have been attributed to differences in their
AA composition [37]. Whey protein contains a higher
proportion of the branched chain amino acids (BCAA)
leucine, isoleucine and valine compared to casein [38].
The BCAAs alone and in particular leucine have been
shown to trigger a potent increase in protein synthesis
in T2DM [39]. Among the other indispensible or essential
amino acids (EAAs), casein contains a higher proportion
of histidine, methionine, phenylalanine and valine than
whey protein [38]. In addition, casein also contains a
higher proportion of several non-EAAs including arginine,
glutamic acid, proline, serine and tyrosine [38].
Gastric emptying, absorption and serum kinetics of milk
proteins
Whey protein is reported to be absorbed faster than ca-
sein [40]. The lower absorption rate of casein in its
native micellar form is because the low pH conditions in
the stomach cause casein to clot and delays gastric
emptying [41]. Therefore, plasma AAs are more rapidly
elevated following whey protein consumption, whereas
changes in plasma AAs are lower and more sustained
following micellar casein consumption [40]. Processing
of whey protein or casein fractions via hydrolysis can
markedly influence absorption and subsequent plasma AA
profiles. A casein hydrolysate is reported to be absorbed
more rapidly than intact micellar casein, resulting in a
greater increase in plasma AAs [42]. Conversely, wheyprotein hydrolysate intake is reported to result in similar
plasma AA levels compared to whey protein concentrate
[43], because of similar rapid rates of gastric emptying and
absorption. The processing of micellar casein by acidifica-
tion and then neutralization with alkali such as sodium
hydroxide or calcium hydroxide to form caseinates also
markedly alters plasma AA profiles compared to micellar
casein [44].
Milk proteins, insulin secretion and glucose control
Insulinotropic effects
Insulin is sensitive to both the composition and concen-
tration of plasma AAs, hence both whey and casein in-
gestion stimulate increased insulin secretion [45,46].
Ingestion of whey protein leads to more rapid secretion
of insulin than micellar casein [40], however, hydrolysis
of casein speeds up the absorption of AAs and secretion
of insulin relative to the micellar form of casein [42].
Insulin has wide-ranging direct and indirect effects on
CHO, fat and protein metabolism, including stimulation
of glucose uptake, glycogen synthesis, lipid uptake, tri-
glyceride (TG) synthesis, protein synthesis and inhibition
of protein breakdown, lipolysis and gluconeogenesis.
Therefore, the stimulation of insulin secretion by different
milk proteins may make a significant contribution to
metabolic effects in insulin sensitive tissues and in particu-
lar skeletal muscle anabolism. Prolonged, elevated fasting
glucose is a key metabolic risk factor, one of the main
characteristics of T2DM and associated with an increased
risk of CVD [47]. Hyperglycaemia develops with increased
insulin resistance and failure of insulin secretion.
Postprandial glycaemia
Management of non-fasting or postprandial glucose re-
sponse is important to minimize prolonged exposure to
high blood glucose levels in individuals both with and
without T2DM [48]. Plasma glucose can increase protein
glycosylation, nonenzymatic glycation products and the
generation of free radicals, as well as decrease nitric
oxide production leading to damage to the macro- and
microvasculature [48]. Of significant importance to dairy
are the milk proteins whey and casein which stimulate
insulin release, and have the potential to alter tissue
glucose uptake and suppress postprandial blood glucose
excursions [43,45,46,49-51].
Many of the studies on the insulinotropic inducing
properties of whey protein or casein have been conducted
in healthy men rather than individuals with impaired
glucose control [43,45,46,49-51]. The AA profile of whey
protein is suggested to contribute to its insulinotropic ef-
fects, however, the protein format has been shown to have
variable effects on insulin secretion. AA-supplemented
drinks containing several insulinotropic AAs found at
high levels in whey protein (e.g. leucine, isoleucine, valine,
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insulinaemic and glycaemic responses [46]. A recent study
showed co-ingestion of these AAs with 9 g whey protein
however did not further augment the suppression of post-
prandial glucose after a CHO meal [52], which may be
due to a ceiling in the stimulation of insulin by free AAs
and AAs derived from intact protein. One study has
shown that insulinotropic effects between intact whey
protein and whey protein hydrolysate does not vary in
healthy individuals at doses of 20-50 g protein [43]. Con-
versely, in a different study whey protein concentrate but
not hydrolysate decreased postprandial blood glucose and
insulin responses in a dose dependent manner (10-40 g)
following an ad libitum mixed meal, although the authors
noted that this was most likely because food intake was
decreased at this free choice meal [49], hence confounding
these effects.
In individuals with T2DM, 18 g whey protein added to
breakfast or lunch resulted in greater insulinotropic
responses, circulating levels of the gut peptide glucose-
dependent insulinotropic polypeptide (GIP), and sup-
pression of postprandial glycaemia than following an
isoenergetic non-dairy protein (lean ham and lactose)
[53]. 55 g whey protein ingested before or with a CHO
lunch also suppressed postprandial glucose in T2DM
patients [54], triggering greater insulinotropic, and gut
peptide (GIP and cholecystokinin, CCK) responses [54].
Gastric emptying was only inhibited with pre-meal whey
protein ingestion, although there was no evidence that
this was any more effective for postprandial glycaemic
control than ingestion with a meal [54]. It is of conside-
rable interest that the acute effects of whey protein on
postprandial blood glucose are comparable to sulfonyl-
ureas and other insulin secretagogues used for the phar-
maceutical management of hyperglycaemia in T2DM.
Sulfonylureas stimulate increased secretion of (pro) insu-
lin by binding to ATP-dependent potassium channels in
pancreatic β-cells [55]. Therefore, there is a rationale for
regular whey protein ingestion before or with meals to
manage postprandial glycaemic responses in individuals
with poor metabolic control or T2DM.
Effects of casein may be less consistent. In an over-
weight group with T2DM, consumption of a casein hy-
drolysate (~30 g) and leucine (~10 g) beverage after
breakfast, lunch and dinner decreased prevalence of
hyperglycaemia over the course of 24 hours [56]. Yet in
another study of patients with long-standing T2DM,
higher 40 g dose casein hydrolysate given at each main
meal did not improve the prevalence of hyperglycemia
over 24 hours [57], possibly attributable to β-cell impair-
ment characteristic of long-term T2DM. Although, even
in long-standing T2DM however, there is some evidence
that the insulin secretory mechanism is retained and can
be re-activated by ingestion of free AA and proteinmixtures including free leucine, free phenylalanine and
wheat protein hydrolysate [58]. Possibly whey protein or
casein could improve hyperglycemia over 24 hours in
individuals with metabolic syndrome or early T2DM char-
acterized by insulin resistance but still functional β-cells.
Chronic fasting glycaemia
To date there have been few randomized controlled tri-
als of longer-term whey protein or casein supplementa-
tion on glycaemic control. In the only study of which we
are aware in overweight and obese individuals, 12 weeks
of 54 g/day whey protein isolate or sodium caseinate
supplementation without any lifestyle intervention re-
sulted in a decrease in fasting blood insulin levels and
insulin resistance, but not fasting blood glucose levels
[59], compared to 12 weeks of glucose supplementation.
Most individuals at the start of the trial had borderline
impaired glucose tolerance (IGT) as well as other meta-
bolic risk factors including high TG, low HDL-C and
high waist circumference [59]. Further long-term trials
of whey protein or casein in individuals with IGT are
warranted based on the evidence from acute trials
showing milk proteins suppress postprandial glycaemia
chronic fasting hyperinsulinaemia and insulin resistance.
Milk proteins and blood lipids
Postprandial dyslipidaemia
Dyslipidaemia is one of the main metabolic risk factors
associated with CVD risk [60]. Metabolic syndrome is
mainly characterized by elevated levels of TG and low
levels of HDL-C [4]. Even in the absence of overt
dyslipidaemia in metabolic syndrome, postprandial
lipaemia can cause transient impairment in endothelial
function and other adverse outcomes [61]. Dairy pro-
teins have potential to suppress postprandial lipaemia
due to their insulinotropic effects, as insulin is known to
inhibit hormone-sensitive lipase and release of FFA [62].
However, studies on the effects of milk protein ingestion
on postprandial lipaemia and chronic dyslipidaemia have
produced mixed findings [63-70]. Two studies in healthy
normolipaemic young men and women reported that 50
g sodium caseinate suppressed the postprandial response
following a 70 g fat bolus, decreasing diet-derived chylo-
microns and FFAs independent of gastric emptying,
compared to an oligosaccharide bolus [64,65]. In another
study of normolipaemic young men and women, how-
ever, ingestion of a lower dose of 23 g casein did not sig-
nificantly modulate the postprandial lipaemic response
to a 40 g fat meal [63].
In a study of obese post-menopausal women, 45 g whey
protein isolate or sodium caseinate with breakfast both
decreased the postprandial appearance of chylomicron-
derived TG as well as the TG:ApoB48 ratio [66]. There
was no change in total cholesterol, LDL-C, HDL-C, FFA
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dominate, it was unsurprising that the cholesterol moieties
did not change postprandially. When investigating the
effect of different types of dairy proteins, also in obese
individuals, a similar bolus of 45 g whey protein isolate,
whey protein hydrolysate, alpha-lactalbumin or casein
glycomacropeptide (GMP) did not differentially alter post-
prandial lipaemia following a fatty meal, although, whey
hydrolysate marginally decreased postprandial suppression
of FFAs relative to the other dairy fractions [68]. In T2DM
patients, 45 g whey protein has been shown to suppress post-
prandial TG, FFA and rate of appearance of chylomicron-
rich lipoproteins after a high-fat meal compared with casein
and also non-dairy (cod and gluten) proteins [69], whilst a
second study in T2DM patients found no response to 45 g
casein on the postprandial TG response following a similar
high-fat meal [67].
As yet the mechanism underpinning the effect of dairy
protein on postprandial lipaemia is not well understood.
Nevertheless, the evidence of acute effects of dairy
protein, particularly whey, on postprandial lipaemia pro-
vides a rationale for longer-term supplementation trials
to manage dyslipidaemia.
Chronic fasting dyslipidaemia
There have to date been few long-term randomized trials
investigating fasting lipids in healthy individuals or those
with adverse metabolic risk. In a study of metabolic syn-
drome, a significant decrease in fasting TG was demon-
strated following a 3 month period of supplementation
of 15 g/day of a fermented whey product, whey malle-
able protein matrix (MPM, comprising whey proteins,
peptides, a probiotic, polysaccharides and calcium) [70],
as were other risk factors but only in individuals with
high pre-existing metabolic risk. Metabolic outcomes in
this study may have been driven by weight loss since
body weight also decreased following MPM supplemen-
tation. In addition, dairy protein supplementation may
provide an indirect way to improve blood lipid profiles
when used in conjunction with low fat or low energy di-
ets to induce weight-loss. Certainly there is experimental
evidence that whey protein can decrease lipid infiltration
into the liver, for example in rodent models of non-
alcoholic fatty liver disease (NAFLD) [71], where hepatic
TG is normalized through dietary treatment. Dairy
protein products appear to have potential to decrease
dyslipidaemia in high-risk individuals, but more studies
are needed.
Milk proteins, vascular reactivity and blood pressure
In epidemiological studies, consumption of dairy prod-
ucts including milk and yogurt is associated with de-
creased risk of hypertension, purported to be driven by a
high content of bioactive peptides [20,72]. Whey proteinand casein both contain the bioactive peptides lacto-
kinins or caseinkinins respectively. In-vitro experiments
indicate these peptides can inhibit ACE activity [25].
ACE is a rate limiting enzyme in the conversion of
angiotensin I to angiotensin II responsible for vasocon-
striction. Therefore, lactokinins or caseinkinins both
have potential to lower blood pressure. Vascular reactiv-
ity is important for glucose disposal and regulation of
blood flow, but is impaired in patients with metabolic
syndrome due to decreased insulin-stimulated vasodila-
tion via the eNOS pathway and suppressed NO produc-
tion in the vascular endothelium [73]. In a recent study
of older overweight adults with impaired vascular endo-
thelial function, 5 g of a novel whey protein-derived
extract increased brachial artery flow-mediated dilation
over a 2 hour period compared to a placebo [74],
although notably without inhibition of ACE activity or
alteration of circulating endothelium factors including
plasma NO, prostacyclin metabolites or endothelin-1
[74]. Evidence for improvements in blood pressure has
been steadily growing in the majority [75-80], although
not all trials [81]. In a study of overweight postmeno-
pausal women, 45 g whey protein isolate and sodium
caseinate had no effect on postprandial arterial stiffness
or on blood pressure over 6 hours [81]. Conversely, in
overweight men and women with mild hypertension, 6
weeks of supplementation with 28 g/day whey protein
concentrate or hydrolysate decreased both systolic and
diastolic pressure as well as mean arterial pressure [75].
Whilst in a group of pre- and hypertensive individuals, 6
weeks of supplementation with 20 g/day whey protein
hydrolysate was shown to further decrease blood pres-
sure compared to intact whey protein [76], despite no
detectable differences in ACE activity. Interestingly, in a
longer 12 week trial of overweight, normo- and hyperten-
sive men and women, 54 g/day whey protein isolate or
sodium caseinate were both reported to decrease blood
pressure and arterial stiffness compared to a glucose con-
trol [77]. Reductions in systolic blood pressure have also
been found following supplementation with fermented or
immune modified milks [78,79], and clinical trials of whey
peptides on blood pressure and vascular function have
produced some promising findings [80].
Milk proteins, immune response and inflammation
A chronic low-grade inflammatory state accompanies
obesity, evident from both elevated systemic inflamma-
tory markers in serum and infiltration of inflammatory
cells into tissues. In obese humans, serum levels of
pro-inflammatory cytokines are elevated and peripheral
blood mononuclear cells are activated [82]. Inflammatory
cytokines can increase insulin resistance and inhibit
glucose uptake in peripheral tissues, as well as increase
proteolysis of skeletal muscle cells. Evidence from in-vitro
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tides have immunosuppressive or immunostimulatory
effects [29]. Kappa-casein has been reported to suppress
lymphocyte proliferation induced by T and B cell mitogens
[83]. Whey protein and its hydrolysates have been to in-
hibit the proliferation of lymphocytes, without the induc-
tion of apoptosis [84]. When mitogens or antigens activate
T lymphocytes they produce cytokines and upregulate cell
surface immune receptors. Whey proteins lactoferrin and
lactoperoxidase have been shown to suppress interferon
secretion from mitogen activated lymphocytes [85].
Animal studies indicate whey protein and casein or their
peptides have immunomodulatory effects in-vivo, but
these are not always in concordance with effects observed
in-vitro [29]. There have been very few studies on whether
whey protein or casein can modulate inflammation and
immune response in individuals with impaired metabolic
control. A recent study in obese non-diabetic individuals
given a high fat mixed meal and whey protein isolate
revealed the CCL5 response, an indicator of immune acti-
vation, in the 4 h postprandial period [86]. In addition, the
MCP-1 response was higher after the whey protein isolate
compared to other proteins [86]. Another recent study in
patients undergoing surgery reported that a whey protein
and CHO drink decreased the postoperative acute phase
response and insulin resistance [87]. Conversely, in a
group of overweight postmenopausal women, a 45 g whey
protein isolate or sodium caseinate bolus did not decrease
postprandial plasma inflammatory markers, IL-6, TNF-α
or acute phase C-reactive protein (CRP) over a 6 hour
period compared to glucose ingestion [81]. Similarly, in a
longer term study in overweight and obese individuals,
whey protein or casein supplementation for 12 weeks was
reported not to influence plasma inflammatory markers
[77]. However, in patients with chronic obstructive disease
(COPD) undergoing a low-intensity exercise therapy,
whey peptide was found to decrease circulating IL-6, IL-8,
TNFα and hsCRP, accompanied by an increased exercise
tolerance [88]. While in-vitro evidence indicates that whey
protein and casein have immunomodulatory effects, more
in-vivo studies are required to assess whether these proteins
can modulate the immune response in individuals with im-
paired metabolic health and low-grade inflammation.
Milk proteins and appetite control
In addition to the direct effects of dairy protein on meta-
bolic health, milk proteins may indirectly drive improve-
ments in metabolic control through the enhancement of
the control of appetite and/or other mechanisms which
aid changes in both body weight and composition. High-
protein foods have long been shown to have favourable
effects on satiety [89-95], and whilst not all studies show
suppression of food intake [96-99], altering the diet in
favour of a higher protein component may well have arole to play in weight control [100-105]. The significant
advantage of a high dairy diet for appetite suppression
and weight loss is the anabolic effect of dairy BCAAs on
lean body mass. BCAAs enhance muscle protein synthe-
sis and skeletal muscle mass, and may protect against
loss of lean mass during periods of weight loss [106]. As
the largest organ group in the body and a highly meta-
bolically active tissue, protection of skeletal mass may in
turn contribute to an improvement in whole body meta-
bolic health.
Whether different protein types have different effects
on food intake however is not as yet well demonstrated,
although there are some studies which have shown
greater satiety for some dairy proteins relative to soy
protein [107,108] or other non-dairy proteins [109].
Interestingly skimmed milk containing both whey pro-
tein and casein has been shown to decrease intake more
than either protein alone in a study of isoenergetic
preloads [110], whilst in another study whey protein in
turn has been shown to suppress intake more than ca-
sein [38]. Various whey protein-derived fractions may
also have differential effects on satiety, including GMP
which has long been purported to suppress food intake.
Supportive evidence however is lacking [106,107]. In an
isoenergetic study of whey protein, whey protein plus
GMP, whey protein-derived alpha-lactalbumin (α-lac),
casein and non-dairy soy protein, it was α-lac that was
shown to suppress intake relative to the other fractions
[111], whilst in a study comparing various forms of
GMP no differential effects on intake were reported
[112]. In a recent study of overweight women from our
laboratory we also found no differential effect of GMP on
energy intake [113] when we gave matched beverages
containing 25 g of whey protein concentrate, GMP, beta-
lactoglobulin (β-lac) and colostrum-derived whey protein,
although greater fullness was induced by β-lac [113].
In one of the early studies, protein-induced appetite
suppression was attributed to both an altered rate of
gastric emptying and an increase in postprandial serum
AA concentrations following whey protein consumption
[38]. Differential effects have also been attributed to
threshold concentrations of total serum AAs in more re-
cent studies of whey protein-induced hunger suppres-
sion when whey and casein were given in a mixed
preload meal [107]. Interestingly in this study a lower
dose (15 g, 10 en% protein) had a greater effect than a
higher dose (38 g, 25 en% protein) [107]. Despite some
differential effects of whey protein fractions in our recent
study [113], we were unable to find a relationship between
circulating levels of total AAs and measures of either
hunger, satiety or food intake. It is possible that tryptophan
may be the most important of the AAs for appetite suppres-
sion since 5-hydroxytryptophan (5HT, serotonin) is an esta-
blished appetite-modulating neurotransmitter [107], but
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mechanisms include regulation of satiety by the gastro-
intestinal (GI) peptides such as glucagon like peptide-1
(GLP-1), CCK and peptide YY (PYY) [114-116]. Circulat-
ing levels of these peptides clearly are altered following a
meal where they have a role in digestion, absorption and
the metabolic fate of ingested nutrients, but there remains
questions around their role in the control of hunger, sati-
ety and eating behavior [97,117]. Our review of the litera-
ture and that of others [118] leads to the conclusion that
the role played by these peptides in the control of food
intake is poorly demonstrated. De Graaf et al., [118]
observed that peptide concentrations induced through ex-
ogenous (pharmaceutical) administration are several-fold
greater than those which occur when a meal is consumed
[118], Whilst GLP-1 and PYY have clear anorectic effects
at high pharmacological levels, following a meal blood
concentrations remain relatively low and neither is likely
to contribute significantly to the satiating effect of protein
or other macronutrients [118]. Circulating CCK levels fol-
lowing a high protein meal are closer to those achieved
following exogenous infusion, yet the evidence that CCK
is a critical driver in human satiety also remains elusive.
Unsurprisingly, the postprandial effects of dairy protein
on GI hormones and energy intake are mixed, with
changes in peptide concentrations rarely driving predict-
able changes in energy intake [118]. For example, in a study
of lean and obese men, 50 g of whey protein resulted in a
prolonged postprandial suppression of ghrelin, increased
GLP-1 and CCK, and as hypothesized, decreased energy
intake of ~10% [95]. Conversely, a study in obese men
reported that 50 g whey protein resulted in a prolonged
suppression of ghrelin, elevation of GLP-1 and CCK [97],
but no detectable changes in energy intake [97]. Hence,
changes in gut satiety peptides in response to pre-meal
protein beverages or after a meal do not reliably translate
into changes in subjective appetite and satiety ratings or
energy intake.
Milk proteins and body weight
Weight-loss diets are widely undertaken to lose excess
abdominal fat, which has implications for metabolic
health since visceral adipose tissue produces inflamma-
tory cytokines, which can inhibit insulin action in
skeletal muscle. Recent evidence has highlighted the role
that dietary protein may play in weight control [105],
with a large scale European Union study, DIOGENES,
reporting that long-term weight loss maintenance was
obtained most effectively in overweight individuals
allowed to eat a high-protein, low glycaemic index (GI)
diet [105]. There have been several long-term studies of
the effect of dairy protein on body composition both in
the presence or absence of a weight-loss or weight-loss
maintenance diet, which are reviewed below.Ad libitum diets for weight-loss
In a randomized controlled trial, supplementation with ~56 g/
day whey protein concentrate for 6 months without any
dietary advice resulted in significantly lower body weight,
fat mass and waist circumference in overweight and obese
individuals compared to an isoenergetic CHO control
[108]. In a second, shorter trial of overweight and obese
individuals with pre-existing metabolic risk however, 54 g/
day of whey protein isolate for 3 months failed to cause
weight loss, but notably metabolic health improved
through decreased fasting blood lipids and insulin
levels [59].
Energy restricted diets for weight-loss
Whilst an energy-restricted diet provides an effective way
to decrease adipose tissue mass and abdominal obesity,
energy intake below basal metabolic requirements also
leads to skeletal muscle loss. Weight-regain after an
energy restricted diet often occurs, in part due to the
decrease in basal metabolic rate (BMR) resulting from loss
of metabolically active skeletal muscle mass. In middle-
aged and older obese participants existing muscle sarco-
penia may further exacerbate this weight-regain [6]. The
effectiveness of whey protein in conjunction with dietary
advice to improve adiposity and lean body mass in
addition to body weight per se has been assessed in several
studies. Whey protein is well established as a driver of
skeletal muscle anabolism, with its constituent BCAAs
such as leucine driving greater protein synthesis [119,120].
As such, a high dairy protein diet may enhance metabolic
health through maintenance of lean body mass during
weight loss. In a randomized trial of obese individuals on
an energy restricted diet, a milk protein based supplement
lead to higher fat loss and preservation of lean mass, as
well as greater overall weight-loss [121]. Another study in
obese men also reported that consumption of a high
protein meal replacement containing whey protein, soy
protein and AAs resulted in greater adipose loss over 12
weeks compared to a standard protein meal replacement
plan [122]. A recent study of overweight elderly has also
shown that supplementation with whey protein plus EAAs
during an energy restricted diet promoted skeletal muscle
protein synthesis compared with standard meal replace-
ments, and in turn promoted greater adipose loss [123].
Unexpectedly in this study however there was no increase
in skeletal muscle mass during EAA supplementation.
Conversely, a shorter-term study of whey protein
supplementation during 8 weeks of weight-reduction
followed by 12 weeks weight-maintenance did not alter
body weight or composition compared to a CHO con-
trol, although the small sample size of only 18 partici-
pants greatly limited the power to detect changes in fat
or lean tissue mass and raises questions on the findings
of this trial [98].
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for adipose loss and/or skeletal mass sparing during
energy restriction is not known. One recent study in
obese individuals on a 6 week energy restricted, weight
loss diet with ~60 g/day casein or whey protein supple-
mentation reported no differences in fat or lean mass
changes between the groups [124]. Casein supplementa-
tion did however result in greater inhibition of protein
degradation despite lower protein synthesis, and an
overall greater positive protein balance. Possibly the
duration of the study was too short for effects on body
composition changes to be detected [124]. In a longer
study, in obese individuals with increased metabolic risk,
both whey protein and casein supplementation were
more effective for maintenance of body weight and
adipose-loss over 12 weeks compared to CHO supple-
mentation, but no differences were found between the
whey protein or casein supplemented groups [125].
Taken together, an energy restricted diet combined with
whey protein or casein supplementation may help to en-
hance body weight and adipose loss whilst maintaining
skeletal muscle mass essential for good metabolic
control. There is however no consensus in support of
differential effects of whey protein versus casein for
weight-loss or improved body composition.
Milk proteins and maintenance of metabolically active
muscle
Skeletal muscle mass is determined by net balance
between the synthesis of new proteins and degradation
of existing proteins. In addition, storage of CHOs in the
form of glycogen and lipids in the form of intramy-
ocellular TGs contribute to minor fluctuations in
skeletal muscle mass. Daily turnover of skeletal muscle
protein in healthy recreationally active humans is around
1-2% day [126]. Protein synthesis is increased postpran-
dially several times a day and decreased during fasting.
The postprandial response appears to be gradually
blunted during aging however, and this lower rate of
muscle protein synthesis may be a key factor in aging
sarcopenia [127]. Exercise is also important, and there is
evidence that skeletal muscle turnover in young, seden-
tary individuals may be lower than active, elderly indi-
viduals [128]. Regular dairy protein supplementation in
individuals with impaired metabolic control exacerbated
by poor muscle mass, often a result of physical inactivity
and/or ageing, has been postulated to prevent further
loss of lean mass and promote skeletal muscle accretion
and enhanced function.
Enhanced muscle mass and function
Milk proteins provide a potent anabolic stimulus due to
their AA composition and insulinotropic effects, although
whether whey protein or casein have greater differentialeffects on muscle mass and/or function is not yet well
understood. An early study in the mid 1990s found that
postprandial whole body protein synthesis was increased
68% after ingestion of whey protein but only 31% after
ingestion of casein [40]. However, casein but not whey
inhibited whole body protein breakdown and so despite
the more rapid appearance of whey-derived AAs, net pro-
tein balance was higher following casein ingestion [40].
Similar observations have been made in later studies
where the slow digestion of casein or milk protein concen-
trate resulted in a more sustained appearance of AAs and
protein accretion, despite lower peak levels of BCAAs
[41,129]. There is also temporal variation in protein syn-
thesis rates, with a recent study using intrinsically labeled
whey protein and casein co-ingested as milk showing that
AA absorption and retention across a lower limb were
similar for both whey protein and casein-derived AAs for
the first 2 hours, but were higher in casein-derived AAs
after >3 hours [130]. Conversely in a study of older men
[37], 20 g of whey protein resulted in greater postprandial
muscle accretion over 6 hours compared to either casein
or casein hydrolysate, despite similar peak rates of serum
AA appearance between whey protein and hydrolysed ca-
sein. This was attributed to the higher leucine content of
whey protein [37], which in combination with its insulin-
otropic effects may be important to overcome insulin
resistance in individuals with poor metabolic control.
Whether post-prandially induced increases in protein syn-
thesis by milk proteins is sufficient to result in net skeletal
mass accretion over time without exercise is yet to be
established. Resistance exercise alone provides an anabolic
stimulus, therefore ingestion of milk protein is likely to be
more advantageous in combination with exercise inter-
ventions to improve metabolic health.
Synergies with exercise
Progressive exercise training causes multiple physio-
logical adaptations in skeletal muscle, which underpin
increased insulin sensitivity, metabolic control and func-
tional changes. These physiological adaptations require
synthesis of new proteins and breakdown of existing
proteins. After acute resistance or endurance type exer-
cise, protein synthesis and protein breakdown are transi-
ently increased dependent upon both the work load and
intensity [126]. Milk protein ingestion in combination
with resistance exercise training may result in greater
skeletal muscle hypertrophy, and in turn increased insu-
lin sensitivity, metabolic control and BMR. On the same
premise milk protein ingestion may be postulated to
accelerate the metabolic adaptation to either resistance
or endurance type exercise training. The main evidence
for this is based on acute increases in whole body or
muscle protein synthesis rates after exercise following
ingestion of milk proteins. For example, after resistance
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casein resulted in an increase in net muscle protein
balance [131]. Direct assessment of myofibrillar protein
synthesis rate 1-6 h post exercise revealed similar in-
creases after 20 g dose of whey protein or casein, although
as expected whey produced a marked increase in the early
period whereas casein produced a more moderate but
prolonged increase [44]. Acute, early phase, post exercise
muscle protein synthesis was also higher following whey
protein hydrolysate compared to casein [132]. By far the
majority of studies of milk protein supplementation on
skeletal muscle synthesis have been conducted in young
healthy individuals or the elderly. Protein synthesis may
be blunted with insulin resistance, therefore whether milk
proteins can enhance post-exercise muscle protein syn-
thesis and also longer term exercise-induced metabolic
adaptations in obesity, metabolic syndrome or T2DM is of
great interest.
Two recent studies in overweight individuals, where
chronic exercise training was combined with milk
protein supplementation, provide little consensus for
increases in muscle mass and metabolic adaptation. In a
6 week randomized controlled trial in overweight young
men, 3 × 30 g/day whey protein isolate combined with
resistance exercise did not result in greater improvement
in metabolic risk compared to a placebo of starch [133].
The test supplements were ingested immediately after
exercise, and also with lunch and dinner each day. The
duration of the intervention was relatively short, given
that metabolic adaptations to training, such as increased
muscle mass and insulin sensitivity, may take over 12
weeks to occur [134]. In a longer-term 6 month study of
weight loss in overweight, older women, 2 × 25 g/day
whey protein isolate in conjunction with an energy
restricted diet and exercise training resulted in both a
trend towards greater weight loss, and MRI-assessed
adipose loss and gain in leg muscle mass [135]. Perhaps
unexpectedly there is as yet limited evidence even in
young healthy participants and bodybuilders that protein
supplementation in combination with resistance exercise
training does lead to greater gains in skeletal muscle mass
[136-138], despite the growing literature supporting
effects on protein synthesis, degradation and balance. In a
study of elderly men undertaking a 12 week progressive
resistance type exercise program, the addition of a protein
supplement, perhaps surprisingly, did not further increase
skeletal muscle hypertrophy and enhance lean body mass
[139]. Habitual protein intake may be a factor which influ-
ences the potential benefits of dairy supplementation in
combination with exercise.
Conclusions
Epidemiological evidence shows dairy consumption to be
associated with a decreased prevalence of metabolic relateddisorders, supported by experimental studies showing milk
protein decreases the prevalence of individual metabolic
risk factors such as hypertension, dyslipidaemia, and mild
hyperglycaemia. As well as via direct mechanisms, there is
also evidence that milk protein may indirectly improve
metabolic health by promoting changes in body compos-
ition in favour of increased lean body mass and decreased
adiposity, particularly during energy-restricted weight loss.
BCAAs, present in high levels in milk protein, enhance
muscle protein synthesis, lean body mass and skeletal
muscle metabolic function. ‘Sarcobesity’, where the adverse
metabolic profile of overweight and obesity is super-
imposed onto a declining, inadequate and poorly functional
skeletal muscle mass, is a rapidly growing health issue, and
lifestyle changes which include an energy restricted diet
and increased activity can lead to significant improvements
in metabolic health. Whey protein supplementation has
positive effects on postprandial and post-exercise glucose,
lipid and protein metabolism and may prevent declining
metabolic health if used in conjunction with lifestyle
changes. Large randomized milk protein supplementa-
tion trials combined with lifestyle changes are still re-
quired however to generate robust evidence supporting
the use of milk protein products to improve or manage
metabolic health.
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